Group 1 - Xinfang Pharmaceutical is facing prosecution for alleged corporate bribery, which may negatively impact its brand reputation, business expansion, and future development [1] - The case is currently in the review and prosecution stage, with the final outcome dependent on legal documents issued by judicial authorities [1] Group 2 - Boji Pharmaceutical's actual controller Wang Tingchun and his concerted parties have collectively reduced their stake in the company by 2.98%, amounting to approximately 11.49 million shares [2] - The share reduction was executed through block trading and centralized bidding, and it is part of a compliant plan that does not alter the company's control [2] - This reduction is likely aimed at optimizing asset allocation, which may temporarily affect investor sentiment [2] Group 3 - Yifang Biotechnology has announced plans to issue H-shares and apply for a listing on the Hong Kong Stock Exchange to enhance its capital strength and competitiveness [3] - The company is currently in discussions with relevant intermediaries regarding the details of the issuance and listing, which have not yet been finalized [3] - The A+H share strategy is expected to broaden international financing channels and support the development of innovative drugs in oncology and other fields [3]

证券日报网讯12月9日晚间，益方生物发布公告称，公司拟聘任香港立信德豪会计师事务所有限公司为 公司发行H股股票并在香港联合交易所有限公司上市的审计机构，为公司出具本次发行上市相关的会计 师报告并就其他相关申请文件提供意见。 ...

(截图来自雪球) 益方生物指，截至目前，公司正与相关中介机构就本次发行上市的相关工作进行商讨，除本次董事会审 议通过的相关议案外，其他关于本次发行上市的具体细节尚未最终确定。本次发行 H 股并上市事项尚 需提交公司股东会审议。 益方生物同时公告，董事会拟聘任香港立信德豪为公司发行H股股票并在香港联合交易所有限公司上市 的审计机构。 益方生物，是一家立足中国具有全球视野的创新型药物研发企业，聚焦于肿瘤、代谢性疾病等重大疾病 领域。公司以解决尚未满足的临床需求为理念，致力于研制出具有自主知识产权、中国创造并面向全球 的创新药物，持之以恒地为患者提供更加安全、有效、可负担的治疗方案。益方生物由王耀林(Yaolin Wang)等多位海归博士联合创办，核心研发团队平均拥有超过20年跨国制药公司主持新药研发和团队管 理的丰富经验。益方生物凭借对疾病作用机理的深入研究和理解，选择具有潜力的药物靶点，从化合物 与靶点的结合构象出发设计药物，在对疾病实现精准治疗的同时，确保优异的人体安全性。基于出众和 丰富的药品开发实力和经验，益方生物自主研发了一系列具有专利保护的创新型靶向药物，覆盖非小细 胞肺癌、乳腺癌、结直肠癌等实体瘤， ...

Group 1 - Jinggong Technology signed a sales contract with Hubei Yuchuang worth 729 million yuan, accounting for 42.16% of the company's audited revenue for 2024 [1] - Heshun Electric is expected to win a bid for a State Grid procurement project worth 107 million yuan, representing 24.97% of the company's 2024 revenue [2] - Yongmaotai plans to invest approximately 400 million yuan in a new intelligent manufacturing project for magnesium-aluminum alloy materials [3] Group 2 - Longi Green Energy announced the termination of its plan to issue global depositary receipts abroad, stating it will not significantly impact its operations [4] - Bai Ao Intelligent is expected to win bids for projects totaling 27.5 million yuan [5] - Lian Biological is planning a change of control and asset purchase, leading to a temporary suspension of its stock [6] Group 3 - Bo Rui Communication intends to acquire 51% of Meijing Technology for 66.49 million yuan [7] - Huitai Medical plans to repurchase shares worth 200 to 250 million yuan for employee stock ownership plans [8] - Yifang Biological is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] Group 4 - Jiuqiang Biological's shareholders signed an agreement for the transfer of 5% of the company's shares to China National Pharmaceutical Investment [11] - Songcheng Performing Arts plans to repurchase shares worth 100 to 200 million yuan for capital reduction [12] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project in Jiangxi Province [13] Group 5 - Xingfu Electronics plans to invest 480 million yuan in a new electronic-grade phosphoric acid project [14] - Jiaao Environmental Protection's stock will be subject to risk warnings due to an administrative penalty [15] - ST Nuotai received a drug registration certificate for a new injection [16] Group 6 - Haimo Technology plans to sell its controlling subsidiary, Xian Sitian Instrument, for 370 million yuan [17] - Jingce Electronics signed multiple sales contracts with a single customer totaling 433 million yuan [18] - Donghua Testing's controlling shareholder plans to reduce its stake by up to 1.99% [19][20] Group 7 - Xingqi Eye Medicine completed the first subject enrollment for a Phase II clinical trial of its eye drop product [21] - Kute Intelligent's controlling shareholder plans to reduce its stake by up to 2% [22] - Dongcheng Pharmaceutical's subsidiary received approval for a new specification of a heparin sodium injection [23] Group 8 - Zhaoyi Innovation is in the process of issuing H-shares and has received regulatory approval [24] - Aokang International's shareholder plans to reduce its stake by up to 3% [25] - Jiamei Packaging's controlling shareholder is planning a change of control, leading to a temporary stock suspension [26] Group 9 - ST Kevin's stock will have its risk warning lifted and will resume trading [27] - Zaiseng Technology's controlling shareholder plans to transfer 6.04% of the company's shares [28] - Lide New Energy's shareholder plans to reduce its stake by up to 1% [29] Group 10 - Srypu terminated its plan to acquire shares and will resume trading [30] - Longjiang Transportation's subsidiary plans to invest 2.679 billion yuan in a graphite mining project [31] - Haowei Group's controlling shareholder has not reduced its stake and has terminated the reduction plan [32] Group 11 - Huilun Crystal received an administrative penalty notice for information disclosure violations [33] - Haiguang Information terminated a major asset restructuring plan [34] - Zhongke Shuguang announced a cash dividend plan [35] Group 12 - Fushuo Technology's share purchase plan was approved by the Shenzhen Stock Exchange [36] - Dongbai Group's shareholder reduced its stake by 25.95 million shares [38]

Group 1 - The Chinese Ministry of Foreign Affairs noted the U.S. decision to allow NVIDIA to sell H200 AI chips to approved customers in China, emphasizing the importance of cooperation for mutual benefit between China and the U.S. [1] - The Chinese Ministry of Commerce highlighted the retail sector as a key focus for developing a complete domestic demand system and promoting high-quality development during the 14th Five-Year Plan period [1] - A new multi-crystalline silicon capacity integration acquisition platform named Beijing Guanghe Qiancheng Technology Co., Ltd. has been established with a registered capital of 3 billion, aimed at exploring strategic cooperation opportunities within the industry [1] Group 2 - The Ministry of Agriculture and Rural Affairs reported that pork supply in November was sufficient, with prices slightly decreasing. The number of breeding sows fell to 39.9 million, marking a 1.1% month-on-month decrease and a 2.1% year-on-year decrease [2] - The Quanzhou Municipal Committee proposed initiatives to enhance infrastructure connectivity with Taiwan, including improving transportation and utilities, and supporting Taiwanese residents in various aspects of life in Quanzhou [2] Group 3 - The draft measures to promote the sales of liquor in Guizhou include supporting collaboration between liquor companies and financial institutions, exploring new financial products, and ensuring product quality while combating market violations [3]

Group 1 - The company held its 8th meeting of the 2nd Board of Directors on December 8, 2025, to discuss the issuance of H-shares and listing on the Hong Kong Stock Exchange [2][3][31] - The board unanimously approved the proposal to issue H-shares and apply for listing on the Hong Kong Stock Exchange [4][8][31] Group 2 - The H-shares will be ordinary shares with a nominal value of RMB 1.00, issued in foreign currency [7] - The listing will take place on the main board of the Hong Kong Stock Exchange, with the timing to be determined based on market conditions and regulatory approvals [10][12] - The issuance will include both a public offering in Hong Kong and an international placement [12][20] Group 3 - The maximum number of H-shares to be issued will not exceed 25% of the total share capital post-issuance, with an option for an additional 15% for over-allotment [14] - The pricing of the shares will be determined based on market conditions and investor demand [16] - The target investors include qualified international institutional investors and eligible domestic investors [18] Group 4 - The funds raised from the H-share issuance will be used for clinical development of core research pipelines, preclinical exploration, and general corporate purposes [33][34] - The board proposed to authorize the board and its authorized persons to handle all matters related to the issuance and listing of H-shares [35][50] Group 5 - The company will apply to register as a non-Hong Kong company in accordance with Hong Kong laws for the purpose of the H-share listing [52] - The board approved a profit distribution plan for retained earnings prior to the H-share issuance, ensuring that both existing and future shareholders share in the profits [54] Group 6 - The board agreed to draft a new set of articles of association applicable after the H-share issuance, in compliance with relevant laws and regulations [58][60] - The internal governance rules will be revised to align with the requirements of the H-share listing [63][65]

Group 1 - Rhein Biotech and Jia Mei Packaging's controlling shareholders are planning changes in company control, with trading suspension starting from December 10, 2025, for Rhein Biotech expected to last no more than 10 trading days and for Jia Mei Packaging no more than 2 trading days [1][2] - Rhein Biotech intends to acquire at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a combination of issuing shares and cash payment, which will make Beijing Jinkangpu a subsidiary included in the consolidated financial statements [1] - Jia Mei Packaging's controlling shareholder is also in discussions regarding a potential change in control, with specific transaction details still under negotiation [2] Group 2 - Haiguang Information has terminated its plan to merge with Zhongke Shuguang through a share exchange, as approved in a board meeting on December 9, 2025 [3] - Huatai Medical plans to repurchase shares with a total amount not less than RMB 200 million and not exceeding RMB 250 million, with a repurchase price cap of RMB 315 per share [4] - Songcheng Performing Arts and Jingu Co., Ltd. also announced share repurchase plans, with Songcheng aiming for a total of RMB 100 million to RMB 200 million and Jingu targeting RMB 30 million to RMB 60 million [4] Group 3 - Xiamen Airport is planning to acquire 100% of the shares of Zhaoxiang Technology, a wholly-owned subsidiary of its controlling shareholder, Xiamen Xiangye Group [5] - Borui Communication intends to acquire 51% of Meijing Technology from related parties for a total price of RMB 66.49 million [6] - Gu Ao Technology's actual controller is planning a change in control, with trading suspension starting from December 8, 2025, and expected to last no more than 3 trading days [6] Group 4 - ST Kevin's application to revoke the risk warning on its stock has been approved, with trading suspension for one day on December 10, 2025, and resuming trading on December 11, 2025 [6] - Huailun Crystal's stock will be suspended for one day starting December 10, 2025, due to false disclosures in its annual reports for 2021 and 2022 [7] - The stock of Jia Ao Environmental Protection will also be suspended for one day on December 10, 2025, due to an administrative penalty notice received from the regulatory authority [12] Group 5 - The company Yongmota plans to invest approximately RMB 400 million in a new project for magnesium-aluminum alloy components for the automotive and robotics industries [20] - ST Ningke is executing a capital reserve transfer plan to increase its share capital, with a total share increase from 684.88 million to 1.62 billion shares [21] - Yingpais plans to increase its shareholding through a combination of bank loans and self-funding, with a total investment of no less than RMB 60 million and no more than RMB 120 million [22]

益方生物(688382.SH)发布公告，为进一步提高公司的资本实力和综合竞争力，深入推进公司发展战 略，更好利用国际资本市场的多元化融资渠道，公司拟于境外发行股份(H股)，并申请在香港联合交易 所有限公司主板挂牌上市。 ...

本文源自：智通财经网 智通财经讯，益方生物(688382.SH)发布公告，为进一步提高公司的资本实力和综合竞争力，深入推进 公司发展战略，更好利用国际资本市场的多元化融资渠道，公司拟于境外发行股份(H股)，并申请在香 港联合交易所有限公司主板挂牌上市。 ...

益方生物表示，截至目前，公司正与相关中介机构就本次发行上市的相关工作进行商讨，除本次董事会 审议通过的相关议案外，其他关于本次发行上市的具体细节尚未最终确定。本次发行H股并上市事项尚 需提交公司股东会审议。 北京商报讯（记者 丁宁）12月9日晚间，益方生物（688382）发布公告称，为进一步提高公司的资本实 力和综合竞争力，深入推进公司发展战略，更好利用国际资本市场的多元化融资渠道，公司拟于境外发 行股份（H股），并申请在香港联交所主板挂牌上市。 ...